AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment

Company Developments - AngioDynamics, Inc. (ANGO) received FDA 510(k) clearance for its AlphaVac F1885 System, which is now indicated for the treatment of pulmonary embolism (PE) [1] - The AlphaVac F1885 System is designed for non-surgical excision of thrombi or emboli from the venous vasculature, enhancing therapy options for PE patients [1][4] - The APEX-AV Study, which enrolled 122 patients, demonstrated the system's efficacy in reducing clot burden and improving right ventricular function [5][6] - AngioDynamics has settled patent litigation with Becton, Dickinson and Company, which is expected to reduce legal expenses and distractions for the company [9] Financial Performance - Over the past six months, ANGO's shares have decreased by 10.5%, while the industry has increased by 20.6% and the S&P 500 has gained 19.8% [2] Market Insights - The global pulmonary embolism market was valued at $1.65 billion in 2022 and is projected to exceed $3.12 billion by 2030, growing at a rate of 8.3% [8] - The growth of the pulmonary embolism market is driven by increasing cancer prevalence and rising healthcare expenditures [8]